List of Excipients in API buprenorphine hcl
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing buprenorphine hcl
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| SpecGx LLC | buprenorphine hcl | 0406-7012 | ANHYDROUS CITRIC ACID |
| SpecGx LLC | buprenorphine hcl | 0406-7012 | LACTOSE MONOHYDRATE |
| SpecGx LLC | buprenorphine hcl | 0406-7012 | MANNITOL |
| SpecGx LLC | buprenorphine hcl | 0406-7012 | POVIDONE |
| SpecGx LLC | buprenorphine hcl | 0406-7012 | SODIUM CITRATE |
| SpecGx LLC | buprenorphine hcl | 0406-7012 | SODIUM STEARYL FUMARATE |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for buprenorphine hcl
Excipient focus: ACESULFAME POTASSIUM
buprenorphine hcl drug variants containing ACESULFAME POTASSIUM
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | buprenorphine hcl | 31722-870 |
| >Company | >Ingredient | >NDC |
buprenorphine hcl drug variants not containing ACESULFAME POTASSIUM
Excipient focus: ANHYDROUS CITRIC ACID
buprenorphine hcl drug variants containing ANHYDROUS CITRIC ACID
buprenorphine hcl drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYANISOLE
buprenorphine hcl drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | buprenorphine hcl | 31722-870 |
| >Company | >Ingredient | >NDC |
buprenorphine hcl drug variants not containing BUTYLATED HYDROXYANISOLE
Excipient focus: CROSPOVIDONE
buprenorphine hcl drug variants containing CROSPOVIDONE
buprenorphine hcl drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| SpecGx LLC | buprenorphine hcl | 0406-7012 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
buprenorphine hcl drug variants containing LACTOSE MONOHYDRATE
buprenorphine hcl drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
buprenorphine hcl drug variants containing MAGNESIUM STEARATE
buprenorphine hcl drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| SpecGx LLC | buprenorphine hcl | 0406-7012 |
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
buprenorphine hcl drug variants containing MANNITOL
buprenorphine hcl drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
buprenorphine hcl drug variants containing POVIDONE
buprenorphine hcl drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CITRATE
buprenorphine hcl drug variants containing SODIUM CITRATE
buprenorphine hcl drug variants not containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
buprenorphine hcl drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| SpecGx LLC | buprenorphine hcl | 0406-7012 |
| >Company | >Ingredient | >NDC |
buprenorphine hcl drug variants not containing SODIUM STEARYL FUMARATE
Excipient focus: STARCH, CORN
buprenorphine hcl drug variants containing STARCH, CORN
buprenorphine hcl drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
buprenorphine hcl drug variants containing WATER
buprenorphine hcl drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| SpecGx LLC | buprenorphine hcl | 0406-7012 |
| Lake Erie Medical DBA Quality Care Products LLC | buprenorphine hcl | 55700-302 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch